Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordCe document a été mis à jour. Il ne s’agit pas de la dernière version publiée. Cliquez ici pour voir la dernière version du fichier.
Évaluation des risques générée par un processus de réglementation
(RA)
last updated: 16 juin 2026
Risk assessment of the ProteqFlu Vaccine - Technical Opinion No. 3637/2013.
EN
16 mai 2013
-
Autorité nationale compétente :National Technical Biosafety Commission ()Setor Policial Sul -SPO Área 5 Quadra 3 Bloco B - Térreo Salas 10 à 14Brasília, DF
CEP - 70610-200, BrésilTéléphone : (5561) 3411-5516,Télécopieur : (5561) 3317-7475,E-mail : ctnbio@mct.gov.br,Site Web : http://www.ctnbio.gov.br,
-
Organisation :Merial Saúde Animal Ltda (Merial)Fazenda São Francisco s/nº - Caixa Postal: 242 - PAULINIA (SP)Paulínia, São Paulo
13140970, BrésilTéléphone : +55 19 3874-8601,Télécopieur : +55 19 3874-8080,E-mail : luciana.soares@merial.com.br,Site Web : http://www.merial.com.br,
-
Proteqflu - equine influenza vaccine| Merial | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins), Use as vaccine
- Commercial release 3637-2013.pdf [ Portugais ]
The ProteqFlu vaccine for import, storage, transport and marketing activities. Its immunogenic agents are recombinant canarypox poxviruses, carrying the gene encoding the HA protein of the equine influenza virus, strains vCP1533 and vCP2241. The vaccine is produced by Merial in Lyon, France, and the product will be imported ready and finished. The ProteqFlu vaccine has been marketed in the European Union (approved by the European Medicines Agency) since 2003, with no relevant records of adverse events involving the GMOs in question.
The ProteqFlu vaccine, intended for active immunization of horses against equine influenza (H3N8) is not potentially causing adverse effects.
FR
FR
The risk classification of the genetically modified organism present in the vaccine is risk class 1 (low individual risk and low risk to the community), the data presented show that this vaccine does not imply additional risks to human health, the environment and the animal production, and the post-commercial release monitoring plan is comprehensive and well structured.
FR
It does not pose a risk to human, animal or environmental health.
The ProteqFlu vaccine, intended for active immunization of horses against equine influenza (H3N8) is not potentially causing significant environmental degradation or harmful to human and animal health.
Molecular traditional methods.
Oui
FR
| Type de fichier | Champs | Fichier(s) : | |
|---|---|---|---|
| Décision de pays ou tout autre communication | Évaluation des risques | 1 | |
